Using Sniper-Cas9 to Minimize Off-target Effects of CRISPR-Cas9 Without the Loss of On-target Activity Via Directed Evolution
February 26th, 2019
12.2K views
Here, we present a protocol to optimize CRISPR-Cas9 to achieve a higher specificity without the loss of on-target activity. We use a directed evolution approach called Sniper-screen to find a mutant Cas9 with the desired characteristics. Sniper-Cas9 is compatible with truncated single-guide RNAs and delivery in a ribonucleoprotein format, well-known strategies for achieving higher specificities.
Overview
This article presents a protocol for optimizing CRISPR-Cas9 to enhance specificity while maintaining on-target activity. The directed evolution approach, termed Sniper-screen, is utilized to identify a mutant Cas9 with improved characteristics.
Key Study Components
Area of Science
- Genetic Engineering
- CRISPR Technology
- Directed Evolution
Background
- Cas9 is an immune protein that targets viral DNA.
- Current Cas9 variants often exhibit off-target activity.
- Improving specificity is crucial for therapeutic applications.
- Directed evolution can help identify Cas9 variants with desired properties.
Purpose of Study
- To develop a method for enhancing the specificity of Cas9.
- To maintain on-target activity while reducing off-target effects.
- To provide a protocol that can be applied to other nucleases.
Methods Used
- Directed evolution using the Sniper Screening System.
- Random mutation of the Cas9 sequence to create a diverse library.
- Simultaneous positive and negative selections for screening variants.
- Electroporation of RNP complexes into HEK293 T cells.
Main Results
- Identification of Cas9 variants with reduced off-target activity.
- Successful transformation and screening of mutant Cas9 libraries.
- Demonstrated compatibility with truncated single-guide RNAs.
- Potential for application in other CRISPR-like systems.
Conclusions
- The Sniper-screen method effectively enhances Cas9 specificity.
- This approach can be adapted for other nucleases in therapeutic contexts.
- Further research is needed to explore the full potential of optimized Cas9 variants.
Frequently Asked Questions
What is the main goal of the study?
The main goal is to optimize CRISPR-Cas9 for higher specificity without losing on-target activity.
How does the Sniper-screen method work?
It uses directed evolution to identify Cas9 variants with improved specificity through simultaneous positive and negative selections.
What are the implications of this research?
Improved specificity in CRISPR technology can enhance therapeutic applications and reduce unintended genetic modifications.
Can this method be applied to other nucleases?
Yes, the techniques developed can be adapted for other CRISPR-like systems.
What are the key steps in the protocol?
Key steps include creating a diverse library of Cas9 variants, screening for specificity, and electroporating RNP complexes into cells.
What is the significance of maintaining on-target activity?
Maintaining on-target activity is crucial to ensure the effectiveness of CRISPR-based gene editing while minimizing off-target effects.
Executive Industry Relevance
CRISPR-Cas9 therapeutic development requires balancing specificity with on-target efficiency to reduce off-target mutagenesis risks. The Sniper-Cas9 directed evolution approach enables identification of high-fidelity nucleases without compromising editing potency, supporting safer genome-editing candidate selection. This method enhances target validation confidence by providing a scalable path to de-risk Cas9-based therapeutics early in discovery.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses through Cas9 variants with minimized off-target DNA cleavage.
- Operational Value: Supports functional target validation by preserving wild-type on-target activity while reducing nonspecific effects.
- Predictive Value: Increases confidence in lead selection by linking nuclease specificity to reduced genotoxic risk in disease models.
Screening & Assay Development
- Assay Readiness: Generates validated Cas9-sgRNA pairs suitable for standardized screening workflows with quantitative indel profiling.
- Reproducibility: Enables library rescreening with alternative sgRNAs to enrich true-positive specificity hits across targets.
- Scalability: Compatible with CMV-PltetO1 dual promoter systems for rapid mammalian-cell performance checks of pooled variants.
Translational & Preclinical Research
- Disease Relevance: Facilitates preclinical continuity by delivering Sniper-Cas9 as ribonucleoprotein (RNP) complexes, maintaining activity in HEK293T cells.
- Mechanistic De-risking: Truncated sgRNA compatibility further improves specificity without on-target loss, enhancing predictive safety profiles.
- Translational Biomarker Alignment: Supports amplicon sequencing-based quantification of on- and off-target editing for biomarker-driven go/no-go decisions.
Pipeline & Workflow Integration
The Sniper-screen method fits within early discovery to lead identification, enabling iterative specificity optimization before preclinical commitment.
- Discovery Biology: Facilitates hypothesis testing via randomized Cas9 library screening with simultaneous positive/negative selection for specificity.
- Screening: Delivers assay-ready variants with quantifiable survival ratios correlating to enrichment of high-fidelity clones after repeated screens.
- Analytics: Enables deep sequencing of amplicons to measure on-target editing and off-target sites with one to three mismatches.
- Translational Research: Supports preclinical advancement by characterizing lead clones across multiple targets for best-performance selection.
- Enterprise Reuse: Adaptable to other CRISPR-like nucleases (e.g., CPF1) without requiring prior structural knowledge, broadening platform utility.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity by decoupling specificity gains from on-target activity loss in engineered Cas9.
- Operational Value: Standardizes workflow via electroporation of RNP complexes and dual-plasmid screening in E. coli for library evaluation.
- Strategic Value: Improves go/no-go decisions by linking nuclease engineering to reduced late-stage biological risk in therapeutic development.
- Portfolio Impact: Enables risk-adjusted prioritization of Cas9-derived candidates through empirical specificity-activity tradeoff resolution.
Implementation Considerations
- Requires molecular biology expertise in directed evolution, plasmid construction, and electroporation.
- Dependent on efficient transformation of BW25141 GOI cells and recovery in SOC medium post-electroporation.
- Necessitates standardized incubation at 32°C for selection and 42°C for colony pooling steps.
- Relies on CFU counting and selective plating to validate library coverage (>10x diversity) and hit enrichment.
- Limited by the need for iterative rescreening to achieve true-positive enrichment, as initial survival rates are typically low.
Biopharma FAQs
Why does null hypothesis testing matter for target validation with Sniper-Cas9?
Null hypothesis testing establishes whether observed on-target editing exceeds background noise, confirming that Sniper-Cas9-mediated effects are specific to the intended locus and not due to random cleavage events.
How does independent variable isolation fit the discovery pipeline in Sniper-screen?
Isolating the Cas9 variant as the independent variable allows researchers to attribute changes in specificity solely to evolved mutations, excluding confounding effects from sgRNA or delivery format.
What quantitative dependent variable measurements enable Sniper-Cas9 evaluation?
Dependent variables include survival ratios on selective versus non-selective plates and amplicon sequencing-based indel frequencies at on-target and off-target sites.
Why do replication requirements matter for cross-functional collaboration in Sniper-Cas9 workflows?
Replicating the screen with surviving pools enriches true-positive hits and ensures consistency between discovery and preclinical teams evaluating lead Cas9 variants.
What statistical analysis capabilities are required before implementing Sniper-Cas9 in lead optimization?
Teams must calculate enrichment ratios from colony counts and perform statistical comparison of off-target mutation frequencies to establish significant specificity improvements over wild-type Cas9.
Chapters in this video
0:04
Title
1:45
Positive and Negative Screening for Evolving Cas9
4:47
Delivery of Cas9 as an RNP with Truncated sgRNA
6:17
RNP Delivery
7:27
Transfection of Plasmids Encoding Sniper-Cas9 and sgRNA
9:01
Targeted Deep Sequencing for the Analysis of On-target and Potential Off-target Sites
9:29
Results: Analysis of Sniper-screen, On-target and Off-target Activities
10:37
Conclusion
